Biomea Fusion, Inc. (BMEA)
0.8689
+0.03
(+3.89%)
USD |
NASDAQ |
Oct 16, 16:00
0.8899
+0.02
(+2.42%)
After-Hours: 20:00
Biomea Fusion Cash from Investing (Quarterly) : 0.00 for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.55M |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | -0.082M |
| September 30, 2024 | -0.186M |
| June 30, 2024 | -0.059M |
| March 31, 2024 | -0.035M |
| December 31, 2023 | -0.008M |
| September 30, 2023 | -0.039M |
| June 30, 2023 | -0.417M |
| Date | Value |
|---|---|
| March 31, 2023 | -1.756M |
| December 31, 2022 | -0.701M |
| September 30, 2022 | 0.225M |
| June 30, 2022 | 7.375M |
| March 31, 2022 | 20.44M |
| December 31, 2021 | 4.55M |
| September 30, 2021 | -0.075M |
| June 30, 2021 | 0.68M |
| March 31, 2021 | -38.51M |
| December 31, 2020 | -0.039M |
| September 30, 2020 | -0.012M |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| REGENXBIO, Inc. | 65.92M |
| Compass Therapeutics, Inc. | -4.977M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.03M |
| Cash from Financing (Quarterly) | 0.159M |
| Free Cash Flow | -47.06M |
| Free Cash Flow Per Share (Quarterly) | -0.1386 |
| Free Cash Flow to Equity (Quarterly) | -9.666M |
| Free Cash Flow to Firm (Quarterly) | -10.03M |
| Free Cash Flow Yield | -78.27% |